Autoimmunity reviews, 2020-10, Vol.19 (10), p.102634, Article 102634
- Mertz, Philippe
- Kleinmann, Jean-François
- Lambert, Marc
- Puéchal, Xavier
- Bonnin, Anthony
- Boulon, Carine
- Diot, Elisabeth
- Hachulla, Eric
- Harid, Naoual
- Harle, Jean-Robert
- Helder, Gil
- Kahn, Jean-Emmanuel
- Kone-Paut, Isabelle
- Lavigne, Christian
- Magy-Bertrand, Nadine
- Maillard, Helene
- Martin, Thierry
- Maurier, François
- Poindron, Vincent
- Schleinitz, Nicolas
- Sibilia, Jean
- Arnaud, Laurent
2020
Details
- Autor(en) / Beteiligte
- Mertz, Philippe
- Kleinmann, Jean-François
- Lambert, Marc
- Puéchal, Xavier
- Bonnin, Anthony
- Boulon, Carine
- Diot, Elisabeth
- Hachulla, Eric
- Harid, Naoual
- Harle, Jean-Robert
- Helder, Gil
- Kahn, Jean-Emmanuel
- Kone-Paut, Isabelle
- Lavigne, Christian
- Magy-Bertrand, Nadine
- Maillard, Helene
- Martin, Thierry
- Maurier, François
- Poindron, Vincent
- Schleinitz, Nicolas
- Sibilia, Jean
- Arnaud, Laurent
- Titel
- Infliximab is an effective glucocorticoid-sparing treatment for Takayasu arteritis: Results of a multicenter open-label prospective study
- Ist Teil von
- Autoimmunity reviews, 2020-10, Vol.19 (10), p.102634, Article 102634
- Ort / Verlag
- Netherlands: Elsevier B.V
- Erscheinungsjahr
- 2020
- Link zum Volltext
- Quelle
- Elsevier ScienceDirect Journals
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1568-9972eISSN: 1568-9972, 1873-0183DOI: 10.1016/j.autrev.2020.102634Titel-ID: cdi_hal_primary_oai_HAL_hal_03634733v1
- Format
- –
- Schlagworte
- Adult, Antirheumatic Agents - therapeutic use, Biotherapies, Female, Glucocorticoid-sparing, Glucocorticoids, Human health and pathology, Humans, Infliximab, Infliximab - therapeutic use, Life Sciences, Male, Prospective Studies, Risk Assessment, Takayasu arteritis, Takayasu Arteritis - drug therapy, Treatment Outcome, Vasculitis, Young Adult